Adela Diagnostic Platform Detects 12 Cancer Types
Adela demonstrated the ability of its genome-wide methylome enrichment platform to detect a broad set of diverse cancers in early stages.
Read MorePosted by Andy Lundin | Apr 19, 2023 | Cancer |
Adela demonstrated the ability of its genome-wide methylome enrichment platform to detect a broad set of diverse cancers in early stages.
Read MorePosted by Chris Wolski | Apr 18, 2023 | Lung Cancer |
New data demonstrates Exai Bio’s novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy.
Read MorePosted by Andy Lundin | Apr 11, 2023 | Cancer |
Foundation Medicine and Bristol Myers Squibb are developing the FoundationOne CDx as a companion diagnostic for repotrectinib.
Read MorePosted by Andy Lundin | Apr 7, 2023 | Unknown Origin & Other Cancer Types |
A simple blood draw can help determine if peptide receptor radionuclide therapy is effective in a patient with neuroendocrine cancer.
Read MorePosted by Andy Lundin | Apr 4, 2023 | Cancer |
Stilla Technologies and Atila BioSystems agreed to market digital PCR kits and assays produced by Atila for use on Stilla’s naica system.
Read More